MedTrace Logo

Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer

NCT04827732 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-09-29

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to determine the maximum tolerated dose (MTD) of hypofractionated IMPT for the reirradiation of locoregionally recurrent rectal cancer.

Conditions

  • Recurrent Rectal Cancer

Interventions

RADIATION

Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy

When feasible it is strongly recommended that radiotherapy begin on a Monday

DEVICE

MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine

-The device that will administer the IMPT

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Michael Waters, M.D. · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-04
Primary Completion
2024-07-29
Completion
2024-11-18
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04827732 on ClinicalTrials.gov